Murlentamab GM102: The Novel Therapeutic in Trial Development Murulentamab GM102 represents the exciting strategy for addressing relapsed multiple tumors. This designed targeted molecule selectively interacts BCMA target expressed on cancerous cells, inducing immune-mediated cytotoxic cytotoxicity . Early clinical results suggest prelimina